Straits Times Index
3,287.75 -5.38 (-0.16%) S&P 500
5,071.63 +1.08 (+0.02%) Dow
38,460.92 -42.77 (-0.11%) Nasdaq
15,712.75 +16.11 (+0.10%) Bitcoin USD
62,877.92 -3,205.84 (-4.85%) CMC Crypto 200
1,346.07 -36.50 (-2.64%)
Crinetics Pharmaceuticals, Inc. (CRNX)
After hours:
| Previous close | 44.22 |
| Open | 44.93 |
| Bid | 43.20 x 100 |
| Ask | 43.39 x 100 |
| Day's range | 43.28 - 45.26 |
| 52-week range | 15.76 - 49.58 |
| Volume | |
| Avg. volume | 804,800 |
| Market cap | 3.376B |
| Beta (5Y monthly) | 0.62 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.69 |
| Earnings date | 02 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 57.92 |
GlobeNewswireCrinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, April 11, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on April 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 121,300 shares of its common stock to ten new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements m
GuruFocus.comInsider Sell: COO Jeff Knight Sells 32,359 Shares of Crinetics Pharmaceuticals Inc (CRNX)
Jeff Knight, the Chief Operating Officer of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX), has sold 32,359 shares of the company on March 22, 2024, according to a recent SEC filing.
GuruFocus.comInsider Sell: Chief Medical and Development Officer Dana Pizzuti Sells 15,089 Shares of ...
Chief Medical and Development Officer Dana Pizzuti of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) sold 15,089 shares of the company on March 20, 2024, according to a recent SEC filing.
